 Lilliam Ambroggio
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 34 | 2023 | 141 | 10.270 |
Why?
| | Pneumonia | 35 | 2023 | 568 | 9.540 |
Why?
| | Anti-Bacterial Agents | 21 | 2024 | 1477 | 3.040 |
Why?
| | Pneumonia, Bacterial | 9 | 2020 | 106 | 2.820 |
Why?
| | Respiratory Tract Infections | 9 | 2024 | 321 | 1.820 |
Why?
| | Child | 76 | 2024 | 18407 | 1.800 |
Why?
| | Emergency Service, Hospital | 19 | 2023 | 1811 | 1.730 |
Why?
| | Guideline Adherence | 5 | 2023 | 492 | 1.710 |
Why?
| | Macrolides | 4 | 2021 | 56 | 1.590 |
Why?
| | Severity of Illness Index | 10 | 2022 | 2551 | 1.580 |
Why?
| | Quality Improvement | 7 | 2018 | 953 | 1.420 |
Why?
| | beta-Lactams | 3 | 2015 | 27 | 1.410 |
Why?
| | Wounds, Gunshot | 2 | 2023 | 188 | 1.390 |
Why?
| | Hospitals, Pediatric | 11 | 2022 | 477 | 1.240 |
Why?
| | Biomedical Research | 4 | 2023 | 585 | 1.220 |
Why?
| | Firearms | 2 | 2023 | 294 | 1.200 |
Why?
| | Infant | 37 | 2023 | 7945 | 1.200 |
Why?
| | Hospitalization | 16 | 2022 | 1754 | 1.200 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1398 | 1.160 |
Why?
| | Bacteremia | 4 | 2019 | 159 | 1.150 |
Why?
| | Child, Preschool | 36 | 2022 | 9093 | 1.150 |
Why?
| | Pneumonia, Mycoplasma | 3 | 2021 | 30 | 1.110 |
Why?
| | Asthma | 6 | 2023 | 2051 | 1.080 |
Why?
| | Prospective Studies | 28 | 2023 | 6232 | 1.070 |
Why?
| | Propensity Score | 2 | 2022 | 224 | 0.920 |
Why?
| | Ultrasonography | 2 | 2018 | 636 | 0.890 |
Why?
| | Humans | 89 | 2024 | 115038 | 0.880 |
Why?
| | Outpatients | 3 | 2015 | 328 | 0.880 |
Why?
| | Thiamine Deficiency | 1 | 2022 | 8 | 0.820 |
Why?
| | Radiography, Thoracic | 4 | 2022 | 163 | 0.820 |
Why?
| | Retrospective Studies | 27 | 2023 | 12547 | 0.790 |
Why?
| | Communicable Diseases | 1 | 2023 | 130 | 0.790 |
Why?
| | Length of Stay | 8 | 2020 | 950 | 0.770 |
Why?
| | Adolescent | 33 | 2023 | 17862 | 0.750 |
Why?
| | Evidence-Based Medicine | 2 | 2015 | 676 | 0.740 |
Why?
| | Ambulatory Care | 3 | 2021 | 478 | 0.660 |
Why?
| | Patient Discharge | 3 | 2022 | 767 | 0.660 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 191 | 0.660 |
Why?
| | Patient Readmission | 4 | 2020 | 606 | 0.630 |
Why?
| | Sepsis | 3 | 2022 | 508 | 0.620 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 499 | 0.610 |
Why?
| | Drug Prescriptions | 3 | 2020 | 239 | 0.600 |
Why?
| | Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.590 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2023 | 60 | 0.590 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2017 | 13 | 0.580 |
Why?
| | Viruses | 3 | 2023 | 94 | 0.580 |
Why?
| | Research Design | 4 | 2021 | 930 | 0.550 |
Why?
| | Male | 38 | 2023 | 55729 | 0.550 |
Why?
| | Alcoholism | 1 | 2022 | 716 | 0.520 |
Why?
| | Microbiota | 4 | 2024 | 648 | 0.500 |
Why?
| | Female | 39 | 2022 | 59610 | 0.500 |
Why?
| | Clinical Decision-Making | 4 | 2022 | 267 | 0.470 |
Why?
| | Research | 2 | 2016 | 395 | 0.440 |
Why?
| | Pediatrics | 3 | 2019 | 981 | 0.430 |
Why?
| | Streptococcus pneumoniae | 2 | 2022 | 134 | 0.410 |
Why?
| | Child, Hospitalized | 3 | 2019 | 38 | 0.410 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2012 | 38 | 0.390 |
Why?
| | Adrenomedullin | 2 | 2021 | 5 | 0.390 |
Why?
| | Prognosis | 7 | 2023 | 3334 | 0.360 |
Why?
| | Fever | 3 | 2022 | 280 | 0.350 |
Why?
| | Odds Ratio | 3 | 2022 | 957 | 0.350 |
Why?
| | Respiratory Sounds | 3 | 2022 | 111 | 0.340 |
Why?
| | Hospital Charges | 1 | 2009 | 38 | 0.340 |
Why?
| | Mycoplasma pneumoniae | 4 | 2022 | 28 | 0.330 |
Why?
| | Simplexvirus | 1 | 2009 | 80 | 0.330 |
Why?
| | Biomarkers | 7 | 2023 | 3419 | 0.330 |
Why?
| | Herpes Simplex | 1 | 2009 | 87 | 0.320 |
Why?
| | Health Resources | 1 | 2009 | 122 | 0.310 |
Why?
| | United States | 9 | 2022 | 12224 | 0.310 |
Why?
| | Feces | 2 | 2021 | 373 | 0.310 |
Why?
| | Critical Illness | 5 | 2024 | 644 | 0.300 |
Why?
| | Utilization Review | 2 | 2018 | 34 | 0.280 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 955 | 0.280 |
Why?
| | Cohort Studies | 10 | 2022 | 4904 | 0.260 |
Why?
| | Inpatients | 2 | 2021 | 378 | 0.260 |
Why?
| | Penicillins | 2 | 2023 | 52 | 0.260 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 323 | 0.260 |
Why?
| | Ohio | 2 | 2016 | 136 | 0.250 |
Why?
| | Influenza, Human | 2 | 2023 | 546 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1177 | 0.250 |
Why?
| | Treatment Outcome | 7 | 2021 | 9122 | 0.240 |
Why?
| | Protein Precursors | 2 | 2021 | 119 | 0.230 |
Why?
| | ROC Curve | 3 | 2022 | 447 | 0.230 |
Why?
| | Multiplex Polymerase Chain Reaction | 2 | 2021 | 45 | 0.220 |
Why?
| | Treatment Failure | 2 | 2015 | 332 | 0.220 |
Why?
| | Logistic Models | 4 | 2021 | 1839 | 0.220 |
Why?
| | Nervous System Diseases | 2 | 2016 | 252 | 0.220 |
Why?
| | Heart Defects, Congenital | 1 | 2009 | 665 | 0.220 |
Why?
| | Pennsylvania | 2 | 2015 | 94 | 0.210 |
Why?
| | Follow-Up Studies | 4 | 2022 | 4420 | 0.210 |
Why?
| | Thiamine | 1 | 2022 | 11 | 0.210 |
Why?
| | Metabolomics | 2 | 2017 | 527 | 0.210 |
Why?
| | Pneumonia, Aspiration | 2 | 2019 | 15 | 0.210 |
Why?
| | Quality of Life | 2 | 2023 | 2359 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 97 | 0.200 |
Why?
| | Pleural Effusion | 1 | 2022 | 47 | 0.200 |
Why?
| | Infant, Newborn | 5 | 2022 | 5040 | 0.190 |
Why?
| | Intensive Care Units | 3 | 2021 | 618 | 0.190 |
Why?
| | Arthritis, Infectious | 1 | 2022 | 49 | 0.190 |
Why?
| | Nucleic Acids | 1 | 2022 | 59 | 0.190 |
Why?
| | Blood Culture | 2 | 2019 | 9 | 0.190 |
Why?
| | Safety | 1 | 2023 | 297 | 0.190 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2019 | 147 | 0.190 |
Why?
| | Virus Diseases | 1 | 2023 | 196 | 0.190 |
Why?
| | Pediatric Emergency Medicine | 1 | 2021 | 15 | 0.190 |
Why?
| | Aftercare | 1 | 2022 | 186 | 0.190 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 186 | 0.180 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2021 | 40 | 0.180 |
Why?
| | Osteomyelitis | 1 | 2022 | 102 | 0.180 |
Why?
| | Gastroenteritis | 1 | 2021 | 65 | 0.180 |
Why?
| | International Cooperation | 1 | 2021 | 172 | 0.180 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 217 | 0.170 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2019 | 1 | 0.170 |
Why?
| | Physicians | 2 | 2021 | 771 | 0.170 |
Why?
| | State Medicine | 1 | 2019 | 18 | 0.170 |
Why?
| | Societies | 1 | 2019 | 37 | 0.170 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 50 | 0.170 |
Why?
| | Clinical Deterioration | 1 | 2019 | 4 | 0.170 |
Why?
| | Risk Factors | 8 | 2022 | 8642 | 0.160 |
Why?
| | Central Nervous System Diseases | 1 | 2019 | 61 | 0.160 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2018 | 19 | 0.160 |
Why?
| | Diarrhea | 1 | 2020 | 171 | 0.160 |
Why?
| | Cytomegalovirus | 1 | 2019 | 145 | 0.160 |
Why?
| | Prednisolone | 2 | 2020 | 76 | 0.160 |
Why?
| | Infectious Disease Medicine | 1 | 2018 | 10 | 0.160 |
Why?
| | Pilot Projects | 1 | 2023 | 1375 | 0.160 |
Why?
| | Pandemics | 2 | 2023 | 1321 | 0.160 |
Why?
| | Influenza B virus | 1 | 2018 | 34 | 0.150 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2018 | 40 | 0.150 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 182 | 0.150 |
Why?
| | Observer Variation | 2 | 2016 | 298 | 0.150 |
Why?
| | Prednisone | 2 | 2020 | 231 | 0.150 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 257 | 0.150 |
Why?
| | Suicidal Ideation | 1 | 2022 | 397 | 0.150 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 182 | 0.150 |
Why?
| | Patient Transfer | 1 | 2019 | 143 | 0.140 |
Why?
| | Antibody Formation | 1 | 2018 | 267 | 0.140 |
Why?
| | Models, Statistical | 1 | 2020 | 602 | 0.140 |
Why?
| | Immunization Schedule | 1 | 2018 | 184 | 0.140 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 4411 | 0.140 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 350 | 0.140 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2018 | 139 | 0.140 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 383 | 0.140 |
Why?
| | Dexamethasone | 2 | 2020 | 317 | 0.140 |
Why?
| | Fatal Outcome | 1 | 2017 | 285 | 0.140 |
Why?
| | Caregivers | 1 | 2023 | 712 | 0.140 |
Why?
| | Intersectoral Collaboration | 1 | 2016 | 56 | 0.130 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 231 | 0.130 |
Why?
| | Hospitalists | 1 | 2019 | 173 | 0.130 |
Why?
| | Physical Examination | 1 | 2017 | 221 | 0.130 |
Why?
| | Health Services Research | 1 | 2018 | 371 | 0.130 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 124 | 0.130 |
Why?
| | Palliative Care | 1 | 2021 | 639 | 0.130 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 300 | 0.130 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2017 | 482 | 0.120 |
Why?
| | Emergency Medicine | 1 | 2018 | 220 | 0.120 |
Why?
| | Anaphylaxis | 1 | 2017 | 148 | 0.120 |
Why?
| | Societies, Medical | 1 | 2018 | 678 | 0.120 |
Why?
| | Reproducibility of Results | 3 | 2017 | 2799 | 0.120 |
Why?
| | Inservice Training | 1 | 2015 | 107 | 0.120 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1435 | 0.110 |
Why?
| | Precision Medicine | 1 | 2017 | 340 | 0.110 |
Why?
| | Influenza Vaccines | 1 | 2018 | 496 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1214 | 0.110 |
Why?
| | Age Factors | 2 | 2022 | 2894 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 957 | 0.110 |
Why?
| | Binomial Distribution | 1 | 2012 | 4 | 0.110 |
Why?
| | Nasopharynx | 2 | 2023 | 63 | 0.100 |
Why?
| | Ethics, Research | 1 | 2012 | 33 | 0.100 |
Why?
| | Linear Models | 1 | 2015 | 776 | 0.100 |
Why?
| | Penicillin Resistance | 1 | 2012 | 8 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 126 | 0.100 |
Why?
| | Academic Medical Centers | 1 | 2015 | 412 | 0.100 |
Why?
| | Medical Informatics | 1 | 2012 | 91 | 0.100 |
Why?
| | Vulnerable Populations | 1 | 2012 | 134 | 0.100 |
Why?
| | Drug Therapy | 1 | 2012 | 77 | 0.100 |
Why?
| | Comparative Effectiveness Research | 1 | 2012 | 130 | 0.100 |
Why?
| | Metagenomics | 2 | 2023 | 131 | 0.100 |
Why?
| | Plasma | 1 | 2012 | 210 | 0.090 |
Why?
| | Bacteria | 3 | 2022 | 728 | 0.090 |
Why?
| | Hypoxia | 1 | 2016 | 958 | 0.090 |
Why?
| | Information Systems | 1 | 2009 | 61 | 0.080 |
Why?
| | Patient Safety | 1 | 2012 | 277 | 0.080 |
Why?
| | Health Care Costs | 1 | 2012 | 381 | 0.080 |
Why?
| | Acyclovir | 1 | 2009 | 100 | 0.080 |
Why?
| | Overweight | 1 | 2012 | 474 | 0.080 |
Why?
| | Respiration, Artificial | 2 | 2023 | 526 | 0.080 |
Why?
| | Administration, Oral | 2 | 2021 | 730 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 937 | 0.080 |
Why?
| | Databases, Factual | 1 | 2012 | 1132 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 797 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2341 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2020 | 3015 | 0.070 |
Why?
| | Clinical Competence | 1 | 2012 | 899 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1715 | 0.060 |
Why?
| | Hospital Mortality | 2 | 2020 | 776 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2009 | 647 | 0.060 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 67 | 0.060 |
Why?
| | Mass Screening | 2 | 2022 | 1012 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 42 | 0.050 |
Why?
| | Cotinine | 1 | 2023 | 67 | 0.050 |
Why?
| | Tachypnea | 1 | 2022 | 4 | 0.050 |
Why?
| | Adult | 5 | 2024 | 30654 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 48 | 0.050 |
Why?
| | Risk Assessment | 2 | 2022 | 2976 | 0.050 |
Why?
| | Smoke | 1 | 2023 | 127 | 0.050 |
Why?
| | Gestalt Theory | 1 | 2021 | 2 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2023 | 928 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 387 | 0.050 |
Why?
| | Feedback | 1 | 2021 | 146 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2022 | 156 | 0.050 |
Why?
| | Lung | 2 | 2024 | 3595 | 0.050 |
Why?
| | Emergency Treatment | 1 | 2021 | 113 | 0.050 |
Why?
| | Fatigue | 1 | 2022 | 295 | 0.040 |
Why?
| | Documentation | 1 | 2022 | 169 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 2524 | 0.040 |
Why?
| | Calcitonin | 1 | 2020 | 23 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2022 | 299 | 0.040 |
Why?
| | Pneumocystis Infections | 1 | 2019 | 1 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 119 | 0.040 |
Why?
| | Time Factors | 2 | 2022 | 6141 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 87 | 0.040 |
Why?
| | Central Venous Catheters | 1 | 2020 | 39 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 915 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2020 | 251 | 0.040 |
Why?
| | Regression Analysis | 1 | 2022 | 948 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 719 | 0.040 |
Why?
| | Young Adult | 3 | 2022 | 10498 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2019 | 292 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 487 | 0.040 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2018 | 37 | 0.040 |
Why?
| | Data Display | 1 | 2018 | 19 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2020 | 363 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2018 | 197 | 0.040 |
Why?
| | Gene Expression | 1 | 2022 | 1423 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 999 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2021 | 633 | 0.040 |
Why?
| | Bias | 1 | 2017 | 179 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 290 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2017 | 331 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 287 | 0.030 |
Why?
| | Data Collection | 1 | 2018 | 623 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2018 | 522 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 772 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2018 | 776 | 0.030 |
Why?
| | Prevalence | 1 | 2020 | 2255 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2318 | 0.030 |
Why?
| | Aged | 2 | 2022 | 19119 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1355 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1747 | 0.020 |
Why?
| | Primary Health Care | 1 | 2020 | 1512 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4631 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 5519 | 0.020 |
Why?
| | Registries | 1 | 2012 | 1763 | 0.020 |
Why?
|
|
Ambroggio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|